Gabapentin in the Treatment of Post-COVID-19 Neuropathic Pains
Introduction: Neuropathic Pain in Long COVID As the global health system continues to grapple with the long-term consequences of COVID-19, chronic neurological symptoms have emerged as a major challenge for patients and clinicians alike. Among these, neuropathic pain, including burning sensations, tingling, and electric shock-like discomfort, is increasingly recognized in individuals experiencing post-acute sequelae of […]
Cenforce in Chronic Liver Disease: Safety Signals You Should Know
Introduction Cenforce, a widely available generic formulation of sildenafil citrate, is frequently used to manage erectile dysfunction, often without formal prescription or clinical oversight. Although pharmacologically equivalent to branded sildenafil, its use in patients with chronic liver disease raises important safety considerations that are rarely addressed in routine practice. This is especially true in cirrhosis, […]
Gabapentin and Personalized Medicine: Genetic Factors and Optimization of Dosages
Introduction: Gabapentin Enters the Era of Personalized Medicine Gabapentin has long been prescribed for its anticonvulsant and analgesic properties, especially in the treatment of neuropathic pain, fibromyalgia, and chronic pelvic pain. Despite its widespread use, clinical response to gabapentin is highly variable, with some patients experiencing profound relief, and others reporting minimal benefit or intolerable […]
Targeted Microbiome Modulation for Irritable Bowel Syndrome (IBS)
Quick Primer on IBS and the Gut–Brain Axis Irritable Bowel Syndrome (IBS) is a common functional gastrointestinal disorder characterized by abdominal pain, bloating, and altered bowel habits, including constipation (IBS-C), diarrhea (IBS-D), or a mix of both (IBS-M). Affecting up to 10–15% of the global population, IBS is a chronic condition with significant quality-of-life impact […]
Flomax and the Bowel: GI Side Effects of Tamsulosin in Real Life
Introduction Tamsulosin, marketed under the brand name Flomax, is a selective α-1A adrenergic receptor antagonist widely prescribed for the management of benign prostatic hyperplasia (BPH). Its mechanism centers on relaxing smooth muscle in the prostate and bladder neck, thereby improving urinary flow and reducing lower urinary tract symptoms. While generally well tolerated, tamsulosin can exert […]
Vidalista and the Gut: Tadalafil’s Gastrointestinal Footprint
Tadalafil, the active pharmaceutical ingredient in Vidalista, is a long-acting phosphodiesterase type 5 (PDE-5) inhibitor commonly used for the treatment of erectile dysfunction (ED) and benign prostatic hyperplasia (BPH). Its extended half-life, often exceeding 24 hours, allows for flexible dosing, both once daily and as needed, which has contributed to its widespread popularity. However, its […]
Pharmacologic Treatment of MASLD/MASH: GLP-1 Agonists, Resmetirom & Beyond
Rebranding NAFLD/NASH → MASLD/MASH: Why the New Terminology Matters In 2023, a major nomenclature shift redefined the landscape of fatty liver disease: NAFLD (nonalcoholic fatty liver disease) became MASLD (metabolic dysfunction-associated steatotic liver disease), and NASH (nonalcoholic steatohepatitis) was renamed MASH (metabolic dysfunction-associated steatohepatitis). This reclassification, endorsed by hepatology societies including the AASLD in its […]
Endoscopic Submucosal Dissection (ESD) for Early Upper GI Cancers: State of the Art
From EMR to ESD: Evolution of Minimally Invasive Oncologic Endoscopy Endoscopic treatment of early gastrointestinal neoplasia has undergone a major transformation over the past two decades. Endoscopic mucosal resection (EMR) was the initial standard for removing superficial esophageal and gastric lesions, especially in Western practice. However, EMR is inherently limited by piecemeal resection for larger […]
Gabapentin for Functional Dyspepsia: Neuroscience Meets the Stomach
Invisible Pain: Visceral Hypersensitivity as a Target Functional dyspepsia (FD) affects up to 10% of the global population, yet it remains frustratingly difficult to treat. Patients typically present with upper abdominal discomfort, early satiety, bloating, or epigastric pain without any visible structural abnormality on endoscopy. When acid suppression fails and there’s no gastroparesis or peptic […]
Helicobacter pylori Eradication in the Era of Rising Resistance: Vonoprazan-Based Dual & Triple Regimens
Antibiotic Resistance Patterns: Why Traditional Triple Therapy Is Failing For decades, the standard approach toHelicobacter pylori eradication relied on triple therapy, typically aproton pump inhibitor (PPI) plus amoxicillin and clarithromycin for 7 to 14 days, but growing global antibiotic resistance has substantially undermined its efficacy. Clarithromycin resistance now exceeds 20% in many regions, particularly in […]